louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03896308: Reliability of Chinese Version of Verbal Learning Test and Selective Reminding Test
Official title: Test-retest Reliability of the Chinese Version of the Verbal Learning Test and Selective Reminding Test Among People With Mild Cognitive Impairment
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mild Cognitive Impairment
Test-retest Reliability
Lead sponsor: National Yang Ming Chiao Tung University
Sponsor class: OTHER
First posted: 2019-03-29
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Mild cognitive impairment (MCI) is distinguished from healthy aging by cognitive difficulties that are greater than expected for one's age and education. Amnestic mild cognitive impairment (aMCI) is a major sub-type of MCI with noticeable impairments in memory. Approximately 12% of aMCI will progress to AD per year. Guidelines for MCI recommended: controlling vascular risk factors and focusing on behavioral interventions.

Brief summary: Mild cognitive impairment (MCI) is distinguished from healthy aging by cognitive difficulties that are greater than expected for one's age and education. Amnestic mild cognitive impairment (aMCI) is a major sub-type of MCI with noticeable impairments in memory. Approximately 12% of aMCI will progress to AD per year. There are two test to evaluate the effects on memory, but both without Chinese version. This study is to know the test-retest reliability of the Chinese version of the Verbal learning test and Selective reminding test among people with mild cognitive impairment.


Eligibility criteria: Inclusion Criteria:

1. Age≥50 years
2. Complained of memory impairment
3. Chinese Version Verbal Learning Test 10-minute delays ≤ 6 words
4. MMSE score≥24 and CDR score=0.5
5. Activities of daily living are intact
6. DSM-IV criteria for the diagnosis of dementia is not met

Exclusion Criteria:

1. Any significant neurologic disease other than suspected incipient Alzheimer's disease
2. Psychotic features, contraindication of exercise... which could lead to difficulty complying with the protocol

Primary outcomes:
measure: Chinese Version of Verbal Learning Test
timeFrame: Change from baseline at two week
measure: Chinese Version of Selective Reminding Test
timeFrame: Change from baseline at two week
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Yang-Ming University
Study officials:
References:
Clinical trial NCT00346008: Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
Official title: Genetic Epidemiologic Studies of Melanoma in Iceland
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Melanoma (Skin)
Keywords: melanoma
recurrent melanoma
stage I melanoma
stage II melanoma
stage III melanoma
stage IV melanoma
Lead sponsor: National Cancer Institute (NCI)
Sponsor class: NIH
Collaborators: name: National Cancer Institute (NCI)
First posted: 2006-06-29
Enrollment: 2500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes

Brief summary: RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying genes to identify melanoma in patients in Iceland and their family members.

Detailed description: OBJECTIVES:

* Assess the feasibility of Iceland Genomics Corporation (UVS) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in Iceland.
* Assess the feasibility of mutation detection using sequencing and HPLC.
* Determine UVS' ability to create datasets with demographic, epidemiologic and molecular data.

OUTLINE: Participants and patients undergo blood collection and complete lifestyle questionnaires. All patients and population-based controls have DNA samples sequenced for MC1R. Demographic and epidemiologic data on all study participants is collected. Sequencing of the major melanoma susceptibility genes CFDKN2A, CDK4, and MC1R is also performed.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Patients diagnosed with melanoma and selected family members are eligible to participate
* Must live in Iceland

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified

Primary outcomes:
measure: Feasibility to identify melanoma
measure: Feasibility to detect mutation
measure: Ability to create datasets
Secondary outcomes:
Other outcomes:
Locations:
city: Reykjavik
country: Iceland
facility: Iceland Genomics Corporation
Study officials:
affiliation: National Cancer Institute (NCI)
name: Alisa Goldstein, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00927108: Rajavtihi Neuronal Adult Stem Cells Project
Official title: Adult Neuronal Progenitor Stem Cell Project
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Keywords: Adult Progenitor Stem cells
Alzheimer's disease
Parkinson's disease
Multiple sclerosis
Lead sponsor: Department of Medical Services Ministry of Public Health of Thailand
Sponsor class: OTHER_GOV
Collaborators: name: Rajavithi Biomolecular Research Center
First posted: 2009-06-24
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Cell culture
Primary purpose: BASIC_SCIENCE

Brief summary: To study the success of Oligodendrocyte progenitor cell culture project in Rajavithi Hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the Biomolecular Research Center. This study aims to produce the reproductive clone of neuronal development protocols and advance projects. Neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of Alzheimer's disease, Multiple sclerosis, and Parkinson's disease respectively in next phase of clinical trials.


Eligibility criteria: Inclusion Criteria:

* Patients who have elective craniotomy or.
* Patients who have elective ventriculostomy surgery or.
* Patients who have elective muscle biopsy or nerve biopsy.
* Patient who have emergency craniectomy for life threatening from emergency medical and surgical conditions such as Brain herniation or head injury

Exclusion Criteria:

* Central nervous system infection for example tuberculous or any bacterial infection, Viral infection, fungal infection.
* Central nervous system Tumor, Malignancy and metastasis.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Rajavithi Hospital
Study officials:
affiliation: Department of Medical Services Ministry of Public Health of Thailand
name: Subsai Kongsaengdao, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01369108: Clinical Study on a New Flowable Composite as a Restorative in Adult Teeth
Official title: Clinical Evaluation of a Low Shrinkage Flowable Resin Composite in Adult Teeth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dental Caries
Keywords: small Class I
molar and premolar
low stress flowable composite
adult
Restoration
small caries lesions
Lead sponsor: Solventum US LLC
Sponsor class: INDUSTRY
Collaborators: name: 3M
First posted: 2011-06-08
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study hypothesis: a new, low polymerization stress flowable composite performs no differently to a conventional, highly filled composite filling material when used as a restorative in small cavities in back teeth.

Study will evaluate the clinical performance of a low shrinking flowable composite filling material, compared with a conventional, highly filled composite restorative when used to permanently fill small cavities in molar and premolar teeth in adult patients.

Detailed description: The study will evaluate clinical performance of a low shrink flowable composite filling material and compare it with a conventional, highly filled composite. The study materials will be used to restore small cavities in molar and premolar teeth in adult patients.

Eligibility criteria: Inclusion Criteria:

* 19 years or older
* must give written consent
* be in good general health
* be available for required follow-up visits
* have at least 28 teeth

Exclusion Criteria:

* has rampant, uncontrolled caries
* has advanced, untreated periodontal disease
* heavy use of smoking tobacco (2 packs or equivalent a day)or chewing tobacco
* has systemic or local disorders that contra-indicate the dental procedures needed in this study
* has evidence of xerostomia
* has evidence of severe bruxing or clenching, or in need of Temporomandibular Joint (TMJ) related therapy
* is pregnant at time of screening or tooth restoration
* has known sensitivity to acrylates or related materials

Primary outcomes:
measure: Clinical Performance by Cvar & Ryge Scores
timeFrame: baseline, 6, 12 and 24 months
measure: Clinical Performance by VAS (Pain Scale)
timeFrame: baseline, 6, 12 and 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham School of Dentistry, 605 School of Dentistry Building, 1919 7th Avenue South
state: Alabama
Study officials:
affiliation: Unversity of Alabama at Birmingam Dental School
name: John O Burgess, DDS, MS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lawson NC, Radhakrishnan R, Givan DA, Ramp LC, Burgess JO. Two-year Randomized, Controlled Clinical Trial of a Flowable and Conventional Composite in Class I Restorations. Oper Dent. 2015 Nov-Dec;40(6):594-602. doi: 10.2341/15-038-C. Epub 2015 Aug 3.
Clinical trial NCT03585608: Optic Nerve Sheath Diameter in Patients Undergoing Palatoplasty
Official title: Effect of Neck Extension on Optic Nerve Sheath Diameter in Patients Undergoing Palatoplasty
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cleft Palate
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2018-07-13
Enrollment: 30
Sex: ALL
Minimum age (years): 6
Maximum age (years): 24
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have undergone a palatoplasty with cleft palate and who are 6 months or older and under 24 months

Brief summary: The purpose of this study is to evaluate the change of the optic nerve sheath diameter according to the change of the neck position in pediatric patients undergoing palatoplasty.

Detailed description: Palatoplaty is performed under neck extension in patients with cleft palate. The purpose of this study is to evaluate the effect of neck extension on the ultrasonographic optic nerve sheath diameter during palatoplasty.

Eligibility criteria: Inclusion Criteria:

* Patients who have undergone a palatoplasty with cleft palate and who are 6 months or older and under 24 months
* Patients who agree to voluntarily participate in this study
* Patients with ASA class 1-2

Exclusion Criteria:

* History of diagnosis of neurologic or ophthalmic disease
* History of neurosurgery or ophthalmic surgery
* Patients who refused to participate in clinical studies

Primary outcomes:
measure: Difference in optic nerve sheath diameter
timeFrame: 10 minutes after neck extension
Secondary outcomes:
measure: Difference in optic nerve sheath diameter
timeFrame: at end of surgery with the neck extended
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan medical Center
city: Seoul
country: Korea, Republic of
facility: Young-Kug Kim
Study officials:
affiliation: Asan Medical Center
name: Young-Kug Kim, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03602508: Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Official title: Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overactive Bladder (OAB)
Keywords: darifenacin
fesoterodine
trospium
solifenacin
oxybutynin
tolterodine
Betmiga
YM178
mirabegron
Overactive bladder
propiverine
antimuscarinics
OAB
imidafenacin
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2018-07-27
Enrollment: 5589
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patient (aged ≥18 years; except for Taiwan ≥20 years old) with overactive bladder who received pharmacological treatment between 1st July 2015 and 29th February 2016.

Brief summary: The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.

This study will also assess the persistence to the overall Overactive bladder (OAB) treatments of a patient, regardless of treatment discontinuation or switch to other OAB medications.

Detailed description: This study is entirely descriptive using secondary medical claim and pharmacy prescription data. No formal comparisons between users of mirabegron and antimuscarinic will be made. Furthermore, no a priori hypothesis testing is intended.

Eligibility criteria: Inclusion Criteria:

* Patient with a new prescription of the index medication within the index period;
* Patient received orally administered monotherapy for OAB on index date.

Exclusion Criteria:

* Patient with prior dispensing record of the index medication during the pre-index period;
* Patient received onabotulinumtoxin A and/or surgical intervention as part of the OAB treatment between the pre index and post-index period;
* Patient diagnosed with stress incontinence (International Classification of Diseases-10 (ICD-10) N39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) before index date;
* Patient with urinary tract infection (ICD-10 N30.0 or equivalent) (for National Health Insurance Research Database (NHIRD) and Health Insurance Review and Assessment (HIRA) database) or a co-prescription of any antibiotics (for NostraData) on index date.

Primary outcomes:
measure: Patients persistence to the index medication
timeFrame: Up to 12 months
Secondary outcomes:
measure: Patients persistence to the overall Overactive Bladder (OAB) treatment regardless of treatment switching to other OAB medications
timeFrame: Up to 12 months
Other outcomes:
Locations:
city: Sydney
country: Australia
facility: Site AU10000
city: Seoul
country: Korea, Republic of
facility: Site KR82001
Study officials:
affiliation: Astellas Pharma Singapore Pte. Ltd.
name: Central Contact
role: STUDY_DIRECTOR
References:
Clinical trial NCT03889808: Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.
Official title: Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Clostridium Difficile
Inflammatory Bowel Diseases
Lead sponsor: Hospital Universitari de Bellvitge
Sponsor class: OTHER
First posted: 2019-03-26
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study would include 400 patients with IBD (Crohn's disease and ulcerative colitis).

Brief summary: The objective of this study to evaluate the seroprevalence of anti-bodies against C. difficile toxins A and B and the asymptomatic carriage of C. difficile in IBD patients according to the need and type of immunosuppressive therapy. The ultimate goal is to identify, among IBD patients, those with the highest risk of CDI.


Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* Diagnosed of IBD, either Crohn's disease or ulcerative colitis
* Age: \>18 and \<65 years
* Time since diagnoses of IBD ≥ 6 months
* Present with the criteria included in any of the 4 specified groups in the study population

Exclusion Criteria:

* History of documented CDI
* Active CDI at the moment of study inclusion
* Any of the following immunosuppressive conditions: HIV infection, Liver cirrhosis, CKD stage IV, Receiving chemotherapy, Transplant (solid organ or hematological), Concomitant neoplasia, Hypogammaglobinemia.

Primary outcomes:
measure: Prevalence of Clostridium difficile anti-toxin Abs in patients with IBD
timeFrame: 0 days
measure: Prevalence of asymptomatic carrier of Clostridium difficile in patients with IBD
timeFrame: 0 days
measure: Study the relationship between the different maintenance therapies for IBD and C. difficile anti-toxin Abs and asymptomatic carriers.
timeFrame: 0 days
Secondary outcomes:
Other outcomes:
Locations:
city: Hospitalet de Llobregat
country: Spain
facility: Hospital Universitari de Bellvitge
state: Barcelona
Study officials:
affiliation: Hospital Universitari de Bellvitge
name: Jordi Guardiola, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06202508: Fetal Death in Utero in the Internship Experience of Midwifery Students : an Unavoidable Experience?
Official title: Fetal Death in Utero in the Internship Experience of Midwifery Students : an Unavoidable Experience?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fetal Death in Utero
Keywords: Fetal death in utero
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2024-01-11
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Midwifery student of the Strasbourg school of medicine having experienced the discovery of a fetal death in utero in a birth room internship

Brief summary: Fetal death in utero and the psychological and professional impact it could have on the midwifery student in training. Fetal death in utero corresponds to the spontaneous cessation of cardiac activity, from 14 weeks of amenorrhea.

For a large proportion of midwifery students, fetal death in utero is a situation encountered in the field. Despite the theoretical courses, a student does not expect to encounter this type of situation during the internship: it is delicate for both the supervising caregivers and the student. The purpose of this study is to demonstrate the impact that this situation could have on the midwifery student, both psychologically and in terms of their professional project.

Detailed description: The aim of the research is to highlight the psychological and professional impact of in utero fetal death among midwifery students in Strasbourg.

Eligibility criteria: Inclusion criteria:

* Age ≥18 years
* Midwifery student of the Strasbourg school of medicine of 3rd year or more
* having experienced the discovery of a fetal death in utero in a birth room internship
* having participated in the follow-up of an in utero fetal death in the birth room
* Agreed to participate in the interview and did not express opposition to the reuse of their data for the purpose of this research

Exclusion Criteria:

- Subject who expressed opposition to participating in the study

Primary outcomes:
measure: To highlight the psychological and professional impact of in utero fetal death on Strasbourg midwifery students.
timeFrame: Approximately 10 months after a midwifery student was in charge of a case of fetal death in utero
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Gynécologie Obstétrique - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT04264208: HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Official title: Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Prostate Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
First posted: 2020-02-11
Enrollment: 4
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

Detailed description: Primary Objective:

1. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI.
2. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to treatment and predict progression free survival (PFS) at 24 months.

Eligibility criteria: Inclusion Criteria:

* Patients must be at least 18 years of age;
* Patients must be able to provide informed consent;
* Histologically proven low-grade or intermediate-grade prostate cancer (PC)
* Scheduled to undergo targeted local therapy (HDR brachytherapy).

Exclusion Criteria:

* Inability to lie still for the entire imaging time;
* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);
* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance;
* Metallic implants (contraindicated for MRI).

Primary outcomes:
measure: Number of Participants With Successful Assessment of PET Based PC Lesions
timeFrame: Day 1 (first scan) and 2 weeks (second scan) relative to baseline. First scan was approximately 2 months prior to HDR treatment
measure: Number of Participants for Which an Assessment of PET Based Therapeutic Response to HDR is Successfully Obtained
timeFrame: Day 1 (first scan) and 2 weeks (second scan) relative to baseline. First scan was approximately 2 months prior to HDR treatment
measure: Progression Free Survival (PFS)
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford Cancer Center
state: California
Study officials:
affiliation: Stanford University
name: Andrei H Iagaru, MD
role: PRINCIPAL_INVESTIGATOR
References: